MIT has been selected by the National Science Foundation (NSF) as an Innovation Corps (I-Corps) Node, and awarded $4.2 million in order to develop programs and resources that will accelerate the translation of fundamental research to practical applications.
Insect larvae-based feed additive/vaccine maker shifts focus to farmed shrimp These trays show R&D scale growth conditions for the insect larvae VakSea uses to produce its immune-boosting proteins.
Industrial IoT solutions innovator Machfu announced today that it is moving its corporate headquarters from the Germantown Innovation Center’s award- winning incubator program to commercial Class A office space in Rockville, Maryland. Machfu’s new headquarters will encompass 5,000 square feet of The Grove 270, a LEED Gold certified and Energy Star-awarded office complex.
Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). These life-threatening diseases have a high mortality rate and often require limb amputations due to complications. The drug, VLX-1005, is the only therapeutic in development that strikes at the source of HITT and has performed impressively in clinically relevant animal models. Additionally, it has demonstrated preservation of insulin secretion and promotion of beta cell survival in newly-diagnosed type I diabetes patient samples, providing significant opportunities for market expansion into diabetes.
Insect larvae-based feed additive/vaccine maker shifts focus to farmed shrimp These trays show R&D scale growth conditions for the insect larvae VakSea uses to produce its immune-boosting proteins. Courtesy photo. Vaccinating aquatic animals is a time- and labor-intensive activity that also comes at great cost to aquaculture operators, most of whom would prefer to avoid…
When: Thursday, September 20, 2018 4:00 – 7:00 PM EST
Where: Columbus Center 701 E Pratt St Baltimore, MD 21202
Join us in envisioning a future that weaves together big data scientists with makers, medical doctors with apparel designers, cut & sew craftsman with artificial intelligence coders. An evening of looking back on the textile mills that once built our city and seeing the new mills of tomorrow filled with smart garments, technical textiles and wearables. Visit the displays of Baltimore companies with athletic apparel, high fashion and medical devices made with functional textiles. Most importantly, see how this new fabric of Baltimore engages you.
Silver Spring-based United Therapeutics Corp. announced Tuesday that it will pay a California company $95 million to develop a new form and delivery method of its flagship Remodulin drug to treat pulmonary arterial hypertension.
BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products.
In healthcare, immersive technology has a number of benefits. Many of these have been demonstrated in a number of ways, whether that is through distracting from pain, or helping to train new doctors. One of the most promising is how virtual reality (VR) can assist in surgery. This technology is being introduced to the Children’s National Health System in Washington D.C.
You have one week left to submit your proposal for our $100K pediatric pitch competition focused on pediatric cardiovascular devices that meet a significant unmet need. The submission deadline is Sept. 10.
If chosen as a finalist, you will have an opportunity to pitch your device to our distinguished panel of judges on Sept. 23 as part of our annual pediatric device symposium.
